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1. Introduction 
Regulation of the tRNA methylases is, as yet, 
only poorly understood, but alteration in specificities 
and levels of activities of these enzymes has been ob- 
served after virus infection [ 1 ] , latent virus induction 
[2, 31, in transformed cells [4], and in neoplasms 
[5- 111. Naturally occurring inhibitors of the tRNA 
methylases have been observed after lambda bac- 
teriophage induction [2] and in normal adult animal 
tissues [ 121. Adenosine [ 131, adenine, and several 
cytotoxic analogs of these compounds [ 141 were 
found to be inhibitors of tRNA methylating enzymes. 
These original findings have been confirmed and ex- 
tended by other investigators [ 151. In this paper, 
we report that four adenosine analogs which are cyto- 
kinins [ 161 have been found to be inhibitors of 
transfer RNA methylating enzymes in vitro. These 
compounds include 6-furfurylamino purine riboside 
(Kinetin riboside), N6 -(A’-isopentenyl) adenosine, 
N6 -(trans-4-hydroxy-3-methylbut-2-enyl) adenosine 
(zeatin riboside), and 6-benzylamino purine riboside. 
Each of these cytokinins inhibited the rate at which 
14CH3 transfer from 14CH, Sadenosyl methionine 
to methyl-deficient tRNA was catalyzed by enzyme 
extracts from animal and bacterial cells. Kinetin 
riboside was found to be a competitive inhibitor of 
the enzyme-catalyzed methyl transfer from S-aden- 
osyl methionine to guanine in tRNA. Partial puri- 
fication of calf spleen enzymes by precipitation with 
60% saturated (NH4)$04 did not alter the response 
to inhibitors. 
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2. Materials and methods 
2.1. Enzyme preparations 
Cells of E. coli M3S were grown aerobically at 
32” in a medium consisting of 10 g Bactotryptone, 
1 g yeast extract, 7 g NaCl and 0.9 g glucose per 
liter. 
When the population density reached 5 X 10’ 
cells/ml, the cells were harvested by centrifugation 
in the cold and washed with cold saline. Cells of 
E. coli B, harvested in mid-logarithmic growth phase, 
were purchased, as a frozen paste, from Miles Labor- 
atories, Inc. Cells were disrupted by grinding in 
the cold with 3 times their weight of wet alumina 
A-305 and extracted with 0.01 M Tris, 0.01 M 
MgClz, 0.005 M mercaptoethanol buffer, pH 8, 
(SMB) containing 5 pug/ml DNase. The supernatant, 
after centrifugation at 8000 g at 5” for 20 min, was 
centrifuged at 100,000 g for 70 min. This second 
supernatant contained most of the tRNA methylase 
activity of the cells. 
About 6 g of fresh frozen calf spleen was dis- 
rupted by grinding for 2 min at 0” in a Potter-Elve- 
hjem homogenizer in 0,25 M sucrose, 0.015 M MgCl, . 
The suspension was centrifuged at 10,000 g for 20 
min at 5’ and the supernatant then centrifuged at 
100,000 g for 1 hr to yield an extract containing 
tRNA methylase activity. 
2.2. Enzyme assays 
Each assay tube, containing in a vol of 0.3-0.5 
ml 75-100 pg methyl deficient tRNA, 0.02-0.2 
&i 14CH3-S-adenosyl methionine (specific activity 
26-30 mCi/mmole), enzyme extract, and varying 
concentrations of the cytokinins dissolved in SMB, 
North-Holland Publishing Company - Amsterdam 
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Fig. 1. Inhibition of bacterial tRNA methylases by adenosine 
riboside (AR), kinetin riboside (KR) and zeatin riboside (ZR). 
Each incubation tube contained in a vol. of 0.45 ml, 75 fig 
methyl-deficient tRNA, 0.1 MCi l4 C-SAM (specific activity 
55 mCi/mmole), inhibitor dissolved in 0.01 M Tris, 0.01 M 
MgCla, 0.005 M mercaptoethanol, pH 8, and E. coli B en- 
zyme extract (0.1 mg protein) in a final buffer concentra- 
tion of 0.015 M Tris, 0.015 M MgCla, 0.0075 M mercapto- 
ethanol, pH 8. After 30 min incubation at 35” the reaction 
was terminated by addition of hydroxylamine, pH 7.5. 
14C transferred to RNA was measured after precipitation 
and washing of RNA as described above. X = AR, l = KR, 
o=ZR. 
all in a final concentration of 0.0 15 M Tris, 0.015 
M MgClz, 0.007 M mercaptoethanol, pH 8, was in- 
cubated at 35” for 30-90 min. Enzyme levels were 
kept below one half saturation [ 11. 0.2 ml of 1.5 
M NH,OH, pH 7.5, was added to each tube, and 
the incubation was continued for 10 min longer. Sam- 
ples were chilled, and 2 mg carrier RNA, followed 
by 4 ml of 0.5 M NaCl in 75% ethanol were added. 
After a minimum of at least 2 hr at -1 S”, the pre- 
cipitates were collected by centrifugation in the cold. 
Precipitates were extracted with 2 M NaCl [ 17j and 
RNA was reprecipitated from the extracts by addi- 
tion of 50% TCA solution. These precipitates were 
washed in the cold with 10% TCA solution, alcohol, 
and ether. RNA, dissolved in a small volume of 2 M 
NH40H was assayed for radioactivity in a scintillation 
counter. 
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Fig. 2. Inhibition of calf-spleen tRNA methylases by kinetin 
riboside. Each incubation tube contained, in a volume of 
0.43 ml, 75 pg methyldeficient tRNA, 0.08 &i r4C-SAM 
(specific activity 55 mCi/mmole), calf spleen enzyme extract 
(0.77 mg protein), and 400 c(g KR (where used) in a final 
buffer concentration of 0.0 15 M Tris, 0.0 15 M MgCla, 
0.0075 M mercaptoethanol, pH 8. Samples were withdrawn 
from the incubation bath at various time intervals and pro- 
cessed as described above. 
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Fig. 3. Competitive inhibition of tRNA methylation by 
kinetin riboside. 0.45 ml samples containing 75 rg methyl- 
deficient tRNA, 400 fig kinetin riboside (where used), calf- 
spleen enzyme preparation (0.77 mg protein), 0.02-0.2 
&i 14C-SAM (specific activity 55 mCi/mmole), in a final 
buffer concentration of 0.015 M Tris, 0.015 M MgCla, 0.005 
M mercaptoethanol, pH 8, were incubated at 35’ for 60 min. 
Samples were then processed as described above. S = molar 
cont. of SAM. V = cpm incorporated. o = controls. X = sam- 
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2.3. Cytokinins 
Isopentenyladenosine was a gift from Dr. N.J. 
Leonard. Additional samples of this compound 
were purchased from Sigma Chemical Co. The 
sources of the other cytokinins were as follows: 
zeatin riboside, Calbiochem; &benzylamino-purine 
riboside, Sigma Chemical Co., kinetin riboside, 
Nutritional Biochem. Co. 
3. Results 
Earlier experiments had shown that isopentenyl- 
adenosine (IPA) was an effective inhibitor of tRNA 
methylases extracted from calf tissues [ 141. IPA, 
a naturally occurring minor component of tRNA, 
has been reported to exhibit cytokinin activity, cyto- 
toxicity, and antitumor activity [ 16, 18, 191. It 
seemed of interest to investigate the possibility that 
other cytokinins might also be able to inhibit tRNA 
methylation. 
The effects of kinetin riboside, (6-furfurylamino 
purine riboside, KR) which is a synthetic cytokinin, 
and of a naturally occurring cytokinin, zeatin ribo- 
side (ZR), with the chemical structure trans-6-(4- 
hydroxy-3-methyl-but-2-enyl)-aminopurine riboside 
on RNA methylases were tested. As shown in fig. 1, 
KR and ZR inhibited the catalysis, by E. coli ex- 
tracts, of methyl transfer from S-adenosyl-methio- 
nine to methyl-deficient tRNA. Adenosine, which 
was shown earlier to be an inhibitor of tRNA methyl- 
ases of E. coli [ 13- 151 was used here as a reference 
compound (fig. 1). The effects of KR and of ZR 
were found to be equivalent on a molar basis, when 
enzyme concentration and S-adenosyl-methionine 
concentration were kept constant. 
Since earlier experiments had shown that adenine 
and adenosine preferentially inhibit guanine RNA 
methylase, [ 141 tests were made to determine 
whether KR inhibits all the tRNA methylases to an 
equal extent or whether it is selective. E. coli pre- 
parations contain a mixture of tRNA methylating 
enzymes in which uracil methylase is the largest com- 
ponent[1,3,20].Inthepresenceofl.lX 10e3M 
KR, 1.8 X 10e8 M S-adenosyl methionine, and just 
minimally saturating levels of unfractionated E. coli 
M3S enzymes, methyl-deficient tRNA accepted CH, 
groups into uracil and guanine in the ratio of about 
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7: 1, Control preparations, without KR accepted 
uracil and guanine in the ratio of 4: 1. These data 
indicated that guanine methylation was more sensi- 
tive to KR inhibition than was uracil methylation. 
In normal tissue extracts most of the tRNA me- 
thylating activity is represented by guanine RNA 
methylases [8]. Animal tissues seemed, therefore, 
to be a more suitable source for enzymes with which 
to study further the effects of KR on tRNA methyl- 
ation. Fig. 2 shows the time course of methyl trans- 
fer catalyzed by calf-spleen enzymes in the presence 
and absence of KR. These data indicate that the 
rate of methyl-group transfer was decreased by KR 
throughout the period of the incubation. Experi- 
ments were then carried out in the presence of 
1.5 X 1Om3 M KR and varying concentrations of 
S-adenosyl methionine (SAM). The data shown in 
fig. 3 indicate a typical competitive inhibitor rela- 
tionship between KR and the methyl donor, SAM. 
Since IPA is not readily soluble in aqueous 
solutions, control of concentration in earlier experi- 
ments was difficult. It seemed worthwhile to re- 
examine the influence of IPA on bacterial methyl- 
ases under slightly altered conditions. Addition of 
0.1% Tween 80 to the buffer does not interfere 
with tRNA methylase activity. As shown in table 1, 
when IPA was solubilized by the addition of Tween 
80 detergent, it was an inhibitor of tRNA methyl- 
ating enzymes from E. cob. The detergent was also 
used in experiments with 6-benzylamino purine 
riboside. This synthetic cytokinin also caused a 
decrease in the rate of methylation catalyzed by 
either animal or bacterial preparations (table 1). 
4. Discussion 
The studies described here indicate that several 
N6 substituted analogs of adenosine are inhibitors 
of RNA methylating enzymes. Each of the sub- 
stances used in the current studies has been report- 
ed to possess cytokinin activity [ 16, 191 . It should 
be noted that there are analogs which have either 
hydrophobic or hydrophilic substituents at the N6 
position in this group. Some of these cytokinins are 
known to be cytotoxic in animal cells and to possess 
antitumor activity [ 18, 21, 221. In addition, IPA 
has been shown to affect lymphocyte transformation 
[231. 
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Table 1 
Inhibition of tRNA methylases by isopentenyladenosine and by 6-benzylamino purine riboside. 
Inhibitor Inhibitor 
Cont. 
(X lO-3 M) 
Enzyme 
Source 
SAM 14CH, 
Cont. 
(X 10-a M) 
Incorp 
(cpm) 
Inhibition 
(%) 
0 E. coli B 2 
IPA 2.0 E. coli B 2 
0 E. coli B 2 
IPA 2.1 E. coli B 2 
0 E. coli B 2 
IPA 2.0 E. coli B 2 
6BA 1.4 E. coli B 2 
- 
0 E. coli B 0.16 
6BA 1.9 E. coli B 0.16 
0 calf spleen 0.16 
6BA 0.6 calf spleen 0.16 
1.3 calf spleen 0.16 
1.9 calf spleen 0.16 
See the legends to the figures for incubation conditions. 
8260 -r 340 - 
6450 f 330 22 
7675+ 220 - 
5935 f 1 23 
7445 * 145 - 
5935 * 345 19 
6145 + 20 17 
1155+25 - 
930*20 20 
1355+50 - 
1070 * 40 21 
935 f 2 31 
797 * 10 40 
At least one of the factors involved in control of 
tRNA methylase activity in uivo is the occurrence 
of varying levels of intracellular methylase inhibitors. 
Development of a low molecular weight inhibitor 
of uracil methylase in E. coli is associated with lambda 
prophage induction [2,20]. The levels of naturally 
occurring inhibitors of methylases in animal tissues 
vary with age and hormonal state of the animal [ 12 3. 
Nicotinamide has also been found to inhibit tRNA 
methylases [2,4]. It seems possible that the cyto- 
kinins may constitute another class of naturally oc- 
curring regulators of tRNA methylating enzymes. 
However, much additional work will be necessary 
to determine whether the substances described here 
perform such a function in vivo, or whether their 
property of inhibiting tRNA methylases is primarily 
of pharmacologic interest. 
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